Accounts Receivable, after Allowance for Credit Loss, Current of Intra-Cellular Therapies, Inc. from 31 Dec 2012 to 31 Dec 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Intra-Cellular Therapies, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2012 to 31 Dec 2024.
  • Intra-Cellular Therapies, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 31 Dec 2024 was $166,500,000, a 46% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Intra-Cellular Therapies, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2024 $166,500,000 +$52,482,000 +46% 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q3 2024 $145,608,000 +$42,938,000 +42% 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 $145,714,000 +$49,750,000 +52% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $131,157,000 +$49,612,000 +61% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $114,018,000 +$38,829,000 +52% 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q3 2023 $102,670,000 +$41,132,000 +67% 30 Sep 2023 10-Q 02 Nov 2023 2023 Q3
Q2 2023 $95,964,000 +$48,988,000 +104% 30 Jun 2023 10-Q 03 Aug 2023 2023 Q2
Q1 2023 $81,545,000 +$48,713,000 +148% 31 Mar 2023 10-Q 04 May 2023 2023 Q1
Q4 2022 $75,189,000 +$55,033,000 +273% 31 Dec 2022 10-K 22 Feb 2024 2023 FY
Q3 2022 $61,538,000 +$44,603,648 +263% 30 Sep 2022 10-Q 03 Nov 2022 2022 Q3
Q2 2022 $46,976,000 +$31,788,186 +209% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $32,832,000 +$19,170,008 +140% 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $20,156,000 +$9,391,417 +87% 31 Dec 2021 10-K 01 Mar 2023 2022 FY
Q3 2021 $16,934,352 +$9,453,748 +126% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $15,187,814 +$12,834,559 +545% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $13,661,992 +$12,310,979 +911% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $10,764,583 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $7,480,604 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $2,353,255 30 Jun 2020 10-Q 10 Aug 2020 2020 Q2
Q1 2020 $1,351,013 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q3 2017 $6,309 +$5,000 30 Sep 2017 10-Q 08 Nov 2017 2017 Q3
Q2 2017 $61,935 -$36,305 -37% 30 Jun 2017 10-Q 09 Aug 2017 2017 Q2
Q1 2017 $68,200 +$68,200 31 Mar 2017 10-Q 10 May 2017 2017 Q1
Q4 2016 $94,339 +$63,679 +208% 31 Dec 2016 10-K 01 Mar 2018 2017 FY
Q3 2016 $1,309* 30 Sep 2016 10-Q 09 Nov 2016 2016 Q3
Q2 2016 $98,240 +$89,122 +977% 30 Jun 2016 10-Q 04 Aug 2016 2016 Q2
Q1 2016 $0 -$3,315 31 Mar 2016 10-Q 28 Apr 2016 2016 Q1
Q4 2015 $30,660 -$20,943 -41% 31 Dec 2015 10-K 01 Mar 2017 2016 FY
Q2 2015 $9,118 -$210,120 -96% 30 Jun 2015 10-Q 05 Aug 2015 2015 Q2
Q1 2015 $3,315* -$164,472 31 Mar 2015 10-Q 30 Apr 2015 2015 Q1
Q4 2014 $51,603 -$284,715 -85% 31 Dec 2014 10-K 25 Feb 2016 2015 FY
Q3 2014 $124,414 -$126,877 -50% 30 Sep 2014 10-Q 03 Nov 2014 2014 Q3
Q2 2014 $219,238 30 Jun 2014 10-Q 12 Aug 2014 2014 Q2
Q1 2014 $167,787 31 Mar 2014 10-Q 05 May 2014 2014 Q1
Q4 2013 $336,318 +$35,889 +12% 31 Dec 2013 10-K 12 Mar 2015 2014 FY
Q3 2013 $251,291 30 Sep 2013 10-Q 05 Nov 2013 2013 Q3
Q4 2012 $300,429 31 Dec 2012 10-K 25 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.